Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life



Rating:

Share or cite this content

Citations should be made in the following way:
Z. Weiszhar, I. Horvath, G. Losonczy, G. Galffy (Budapest, Hungary). High pretreatment plasma VEGF level is associated with shorter survival in paclitaxel-carboplatin treated non-small cell lung carcinoma patients. Eur Respir J 2013; 42: Suppl. 57, 4488

Member's Comments

No comment yet.

Related content which might interest you: Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Procalcitonin serum levels in patients with stage IV non-small cell lung cancer in first line of chemotherapy Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 Reduction of peak oxygen consumption in patients with non-small cell lung cancer treated with neoadjuvant chemotherapy Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Loss of heterozygosity of PTEN in patients with non-small cell lung cancer treated and not treated with neoadjuvant chemotherapy Source: Annual Congress 2013 –Genetics and genomics of lung disease Year: 2013 Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Is there a difference in response to first line chemotherapy related to age in patients with locally advanced or metastatic non-small lung cancer? Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Changes in lymphocyte subgroups of non-small cell lung cancer patients during chemotherapy Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Outcomes of radical treatment of early stage non-small cell lung cancer Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 The effect of surgical specimen-derived phosphorus and lead concentrations in non-small cell lung cancer patients on disease course Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Screening for intracerebral metastasis in radically treated non-small cell lung cancer patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Mortality in asymptomatic vs. symptomatic patients surgically treated for non-small cell lung cancer (NSCLC) Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Prognostic factors for stage IV lung adenocarcinoma patients receiving retreatment with EGFR-TKI Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC) Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Neutrophil/lymphocyte ratio as a prognostic marker for curative-intent surgery in non-small cell lung cancer Source: International Congress 2015 – Surgery and lung cancer: results and complications Year: 2015 Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015